Pharmalot - Page 2 of 121

Pharmalot

Vertex and Canada hold talks over cystic fibrosis drug, but a deal for newer medicine remains out of reach

By Ed Silverman

Pharmalot

Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests

By Ed Silverman

Pharmalot

Pharmalittle: Trump pushes for Covid-19 vaccine by year’s end; Americans fear pharma will keep raising drug prices

By Ed Silverman

Pharmalot

A majority of Americans fear pharma will use Covid-19 as an excuse to raise prices

By Ed Silverman

Pharmalot

Some Covid-19 trial sponsors never posted other study results in an EU database. Will they hide data again?

By Ed Silverman

Pharmalot

California attorney general says FTC failed to follow ‘best practices’ in approving AbbVie-Allergan deal

By Ed Silverman

Pharmalot

Pharmalittle: White House says Covid-19 vaccine will be free to the ‘vulnerable’; vaccine makers hunt for glass vials

By Ed Silverman

Pharmalot

As quality concerns rise, FDA report shows Indian drug plants inspected more often — and had more problems

By Ed Silverman

Pharmalot

Pharmalittle: Cheap steroid reduced deaths in severe Covid-19 patients; what the FDA decision on hydroxychloroquine means

By Ed Silverman

Pharmalot

A YouTube ‘hit job’ about a Catalyst Pharma rival is posted amid its battle with the FDA

By Ed Silverman

Pharmalot

Pharmalittle: Lilly begins studying RA drug for Covid-19; AstraZeneca to provide Europe 400 million vaccine doses

By Ed Silverman

Pharmalot

A would-be chain of cancer centers wants to treat patients with Right to Try drugs, raising ethical questions

By Ed Silverman

Pharmalot

Antimicrobials benefited from expedited FDA programs more than other drugs

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: U.S. Chamber wants transparency around Covid-19 vaccines; EU to pump billions into vaccine deals

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer CEO says Covid-19 vaccine price won’t be huge; Lilly antibody therapy may be ready by fall

By Ed Silverman

Pharmalot

California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents

By Ed Silverman

Pharmalot

States file a third lawsuit accusing dozens of generic drug makers of price fixing

By Ed Silverman

Pharmalot

Pharmalittle: Fauci encourages fair pricing for Covid-19 products; U.S. plans to start pivotal vaccine trials this summer

By Ed Silverman

Pharmalot

Many Canadian medical societies fail to disclose industry funding in their clinical guidelines

By Ed Silverman

Pharmalot

A judge rules AbbVie is ‘immunized’ from antitrust claims over its Humira patent dealings

By Ed Silverman

Pharmalot

Pharmalittle: Compounders push to make pandemic changes permanent; production concerns seen for Covid-19 monoclonals

By Ed Silverman

Pharmalot

Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

By Ed Silverman

Pharmalot

Pharmalittle: Will AstraZeneca bid for Gilead? University terminates researcher over Covid-19 papers

By Ed Silverman

Pharmalot

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

By Ed Silverman

Pharmalittle: Sanofi steps up Covid-19 vaccine efforts; has a successor to FDA’s Janet Woodcock been found?

Pharmalittle: Will a Covid-19 vaccine protect the elderly? Generic remdesivir to cost up to $79 a dose

Up and down the ladder: The latest comings and goings

Pharmalittle: Europe nears a deal for J&J Covid-19 vaccine; Biogen loses a big patent case

Vertex and Canada hold talks over cystic fibrosis drug, but a deal for newer medicine remains out of reach

Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests

Pharmalittle: Trump pushes for Covid-19 vaccine by year’s end; Americans fear pharma will keep raising drug prices

A majority of Americans fear pharma will use Covid-19 as an excuse to raise prices

Some Covid-19 trial sponsors never posted other study results in an EU database. Will they hide data again?

California attorney general says FTC failed to follow ‘best practices’ in approving AbbVie-Allergan deal

Pharmalittle: White House says Covid-19 vaccine will be free to the ‘vulnerable’; vaccine makers hunt for glass vials

As quality concerns rise, FDA report shows Indian drug plants inspected more often — and had more problems

Pharmalittle: Cheap steroid reduced deaths in severe Covid-19 patients; what the FDA decision on hydroxychloroquine means

A YouTube ‘hit job’ about a Catalyst Pharma rival is posted amid its battle with the FDA

Pharmalittle: Lilly begins studying RA drug for Covid-19; AstraZeneca to provide Europe 400 million vaccine doses

A would-be chain of cancer centers wants to treat patients with Right to Try drugs, raising ethical questions

Antimicrobials benefited from expedited FDA programs more than other drugs

Up and down the ladder: The latest comings and goings

Pharmalittle: U.S. Chamber wants transparency around Covid-19 vaccines; EU to pump billions into vaccine deals

Pharmalittle: Pfizer CEO says Covid-19 vaccine price won’t be huge; Lilly antibody therapy may be ready by fall

California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents

States file a third lawsuit accusing dozens of generic drug makers of price fixing

Pharmalittle: Fauci encourages fair pricing for Covid-19 products; U.S. plans to start pivotal vaccine trials this summer

Many Canadian medical societies fail to disclose industry funding in their clinical guidelines

A judge rules AbbVie is ‘immunized’ from antitrust claims over its Humira patent dealings

Pharmalittle: Compounders push to make pandemic changes permanent; production concerns seen for Covid-19 monoclonals

Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

Pharmalittle: Will AstraZeneca bid for Gilead? University terminates researcher over Covid-19 papers

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?